ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2422

Pregnancy Outcomes in Patients with Interstitial Lung Disease Related to Autoimmune Disease and Sarcoidosis

Stephanie L. Giattino, Amanda M. Eudy and Megan E. B. Clowse, Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: interstitial lung disease, pregnancy and sarcoidosis, Pulmonary Involvement

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Currently published data regarding pregnancy outcomes in patients with interstitial lung disease (ILD) related to autoimmune disease and sarcoidosis is limited, with widely variant outcomes reported. Some guidelines even suggest that these patients must avoid or terminate pregnancy. This study aimed to retrospectively analyze the pregnancy outcomes in a cohort of patients with ILD to help inform our ability to counsel patients on decision-making surrounding pregnancy and to help guide our management throughout pregnancy.

Methods: Medical records from 1/1/1996-9/27/2017 were retrospectively searched for encounters at our center for ICD-9/10 codes associated with pregnancy and ILD, including sarcoidosis. Each chart was reviewed to corroborate the diagnosis of lung disease, confirm that it temporally preceded the pregnancy, and ensure availability of delivery outcomes. Patients were categorized into two groups: sarcoidosis and autoimmune-related ILD (AI-ILD). Differences in categorical variables were analyzed using Fisher’s Exact Test, and continuous variables were analyzed using ANOVA or Wilcoxon rank-sum test.

Results: Of 631 patient charts reviewed, 62 unique patients with 89 pregnancies (5 twins) met inclusion criteria; 63 pregnancies with sarcoidosis (62% biopsy-proven) and 26 with AI-ILD (11 SLE, 1 RA, 3 SSc, 3 PM, 2 SS, 2 EGPA, 2 UCTD, 2 CTD-ILD). The cohort was predominantly black (84.3%), with mean maternal age of 32 years.

In total, there were 62 live births (Table 1), of which 11 were preterm (17.7%). Women in 8 pregnancies (12.9%) required oxygen at the time of delivery; however, only 1 (1.6%) required labor induction for maternal lung disease, and no patients required intubation. Two required ICU stays and no women died. Women with AI-ILD had more preeclampsia, but otherwise had similar pregnancy outcomes to those with sarcoidosis. Minimal differences in pregnancy outcomes and maternal morbidity were found when women with severe lung disease by imaging and/or pulmonary function tests were compared to those mild disease. Women with total lung capacity (TLC) <65% predicted more often required oxygen at delivery and had more C-sections, while women with diffusion capacity (DLCO) <60% predicted had no pregnancy outcome differences compared to women with better levels. The rate of pregnancy termination was similar for women with severe lung disease compared to overall (9.6% and 11.2%, respectively). While black women comprised >90% of the severe subgroups, pregnancy outcomes were similar when compared to non-black women with similar severity.

Conclusion: Pregnancies in women with AI-ILD and especially with sarcoidosis appear to be well tolerated from a pulmonary perspective, even in those with more severe disease by imaging and pulmonary function tests. Our data suggest is it not necessary for these women to avoid or terminate desired pregnancies due to lung disease alone.

Table 1.

Total

Sarcoidosis

AI-ILD

p value

Pregnancies*, no. (%)

89

63 (70.7%)

26 (20.2%)

Maternal age, mean ± sd, y

32.0 ± 5.9

33.4 ± 5.7

28.5 ± 4.9

p=0.0003

Maternal age, range, y

18-42

18-42

19-37

Severe lung disease, no. (%):

· fibrosis on imaging,

· TLC < 65% predicted, AND/OR

· DLCO < 60% predicted

52/87 (49.8%)

35/61 (57.4%)

17/26 (65.4%)

p=0.6

Race, no. (%)

p=1.0

White

10 (11.2%)

7 (11.1%)

3 (11.5%)

Black or African American

75 (84.3%)

53 (84.1%)

22 (84.6%)

Ethnicity, no. (%)

p=1.0

Hispanic

3 (3.4%)

2 (3.2%)

1 (3.9%)

Co-Morbidities, no. (%)

Diabetes Mellitus

5 (6.5%)

4 (7.4%)

1 (4.4%)

p=1.0

Hypertension

10 (12.8%)

6 (10.9%)

4 (17.4%)

p=0.5

Tobacco Use

24 (30.4%)

19 (34.6%)

5 (20.8%)

p=0.3

Alcohol Use

8 (10.5%)

6 (11.5%)

2 (8.3%)

p=1

DMARDs, no. (%)

Prednisone

24 (27%)

9 (14.2%)

15 (57.7%)

p=0.0001

Hydroxychloroquine

12 (13.5%)

0 (0%)

12 (46.2%)

p<0.0001

Azathioprine

15 (16.9%)

0 (0%)

15 (57.7%)

p<0.0001

Tacrolimus

3 (3.4%)

0 (0%)

3 (11.5%)

p=0.02

Neonatal Outcomes

Terminations

10 (11.2%)

6 (9.5%)

4 (15.4%)

p=0.6

Live Births

62

46

16

Gestational Age at Delivery, mean ± sd, weeks

37.8 ± 2.6

37.8 ± 2.6

37.7 ± 2.7

p=0.8

Small for Gestational Age, no. (%)

14 (22.6%)

12 (25%)

2 (14.3%)

p=0.5

Labor & Delivery Outcomes, no. (%)

C-section Delivery

37 (59.7%)

27 (58.7%)

10 (62.5%)

p=0.9

Preeclampsia

8 (12.9%)

3 (6.5%)

5 (29.4%)

p=0.02

Oxygen at delivery

8 (12.9%)

4 (8.7%)

4 (26.7%)

p=0.09

ICU Stay

2 (3.2%)

0 (0%)

2 (12.5%)

p=0.06

Intubations

0 (0%)

0 (0%)

0 (0%)

p=1.0

*Analyses performed on individual pregnancies such that one woman could contribute >1 pregnancy.


Disclosure: S. L. Giattino, None; A. M. Eudy, None; M. E. B. Clowse, UCB Pharma, 5,Janssen, Pfizer, 2, 5,AbbVie, Bristol-Myers Squibb, 2.

To cite this abstract in AMA style:

Giattino SL, Eudy AM, Clowse MEB. Pregnancy Outcomes in Patients with Interstitial Lung Disease Related to Autoimmune Disease and Sarcoidosis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/pregnancy-outcomes-in-patients-with-interstitial-lung-disease-related-to-autoimmune-disease-and-sarcoidosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pregnancy-outcomes-in-patients-with-interstitial-lung-disease-related-to-autoimmune-disease-and-sarcoidosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology